Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-Blind Placebo-Controlled Study.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Raloxifene (Primary)
- Indications Bone resorption
- Focus Therapeutic Use
- 15 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2010 Results were presented at the 11th Annual Congress of the European League Against Rheumatism.
- 02 Jun 2009 Planned end date changed from 1 Jun 2008 to 1 Feb 2010 as reported by ClinicalTrials.gov.